Medigen Vaccine Biologics Total Assets

Latest as of June 2026: NT$4.76 Billion TWD ≈ $149.99 Million USD

Medigen Vaccine Biologics total assets. Based on the latest financial reports, Medigen Vaccine Biologics (6547) holds total assets worth NT$4.76 Billion TWD (≈ $149.99 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Medigen Vaccine Biologics (6547) total market value for the company's overall valuation and market capitalisation.

Total Assets of Medigen Vaccine Biologics (2012–2025)

Total assets of Medigen Vaccine Biologics from 2012 to 2025. This chart illustrates how Medigen Vaccine Biologics's total assets have evolved over time, based on quarterly financial data. See Medigen Vaccine Biologics (6547) share price today for real-time trading data and today's change.

Medigen Vaccine Biologics - Asset Composition Analysis

Medigen Vaccine Biologics Total Assets Breakdown (December 2025)

Medigen Vaccine Biologics total assets breakdown as of December 2025. Medigen Vaccine Biologics's total assets of NT$4.76 Billion consist of 60.1% current assets and 39.9% non-current assets.

Asset Category Amount (TWD) % of Total Assets
Cash & Equivalents NT$0.00 15.1%
Accounts Receivable NT$130.02 Million 3.3%
Inventory NT$393.75 Million 10.0%
Property, Plant & Equipment NT$0.00 0.0%
Intangible Assets NT$21.14 Million 0.5%
Goodwill NT$0.00 0.0%

Asset Composition Trend (2012–2025)

This chart illustrates how Medigen Vaccine Biologics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Medigen Vaccine Biologics working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Medigen Vaccine Biologics's current assets represent 60.1% of total assets in 2025, an increase from 30.0% in 2012.
  • Cash Position: Cash and equivalents constituted 15.1% of total assets in 2025, down from 26.5% in 2012.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 65.0% in 2012.
  • Asset Diversification: The largest asset category is inventory at 10.0% of total assets.

Medigen Vaccine Biologics Competitors by Total Assets

Key competitors of Medigen Vaccine Biologics based on total assets are shown below.

Company Country Total Assets
argenx NV ADR
NASDAQ:ARGX
USA $10.03 Billion
Argen-X
F:1AE
Germany €8.68 Billion
Ascendis Pharma AS
F:A71
Germany €2.00 Billion
Halozyme Therapeutics Inc
NASDAQ:HALO
USA $3.47 Billion
Abivax SA American Depositary Shares
NASDAQ:ABVX
USA $462.21 Million
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
USA $2.19 Billion
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
China CN¥13.56 Billion
SOLENO THERAPEUT. DL-001
F:6XC
Germany €563.83 Million

Medigen Vaccine Biologics - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 22.37 13.70 4.20
Quick Ratio 18.16 10.85 3.03
Cash Ratio 0.00 0.00 0.00
Working Capital NT$2.67 Billion NT$2.27 Billion NT$2.21 Billion

Medigen Vaccine Biologics - Advanced Valuation Insights

This section examines the relationship between Medigen Vaccine Biologics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 5.44
Latest Market Cap to Assets Ratio 0.10
Asset Growth Rate (YoY) -9.9%
Total Assets NT$3.93 Billion
Market Capitalization $407.56 Million USD

Valuation Analysis

Below Book Valuation: The market values Medigen Vaccine Biologics's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Medigen Vaccine Biologics's assets decreased by 9.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Medigen Vaccine Biologics (2012–2025)

The table below shows the annual total assets of Medigen Vaccine Biologics from 2012 to 2025.

Year Total Assets Change
2025-12-31 NT$3.93 Billion
≈ $123.94 Million
-9.85%
2024-12-31 NT$4.36 Billion
≈ $137.49 Million
-28.37%
2023-12-31 NT$6.09 Billion
≈ $191.95 Million
-17.08%
2022-12-31 NT$7.35 Billion
≈ $231.49 Million
+38.66%
2021-12-31 NT$5.30 Billion
≈ $166.95 Million
+51.80%
2020-12-31 NT$3.49 Billion
≈ $109.98 Million
+53.30%
2019-12-31 NT$2.28 Billion
≈ $71.74 Million
+4.30%
2018-12-31 NT$2.18 Billion
≈ $68.78 Million
+2.18%
2017-12-31 NT$2.14 Billion
≈ $67.31 Million
+17.56%
2016-12-31 NT$1.82 Billion
≈ $57.26 Million
+9.91%
2015-12-31 NT$1.65 Billion
≈ $52.09 Million
+36.13%
2014-12-31 NT$1.21 Billion
≈ $38.27 Million
+154.43%
2013-12-31 NT$477.40 Million
≈ $15.04 Million
+217.95%
2012-12-31 NT$150.15 Million
≈ $4.73 Million
--

About Medigen Vaccine Biologics

TWO:6547 Taiwan Biotechnology
Market Cap
$407.56 Million
NT$12.94 Billion TWD
Market Cap Rank
#12600 Global
#435 in Taiwan
Share Price
NT$39.35
Change (1 day)
-7.08%
52-Week Range
NT$35.50 - NT$68.10
All Time High
NT$280.20
About

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more